CLE-905, a potent M1/M4 entering First-in-Human: Similarities to Xanomeline & targeted differentiation from Cobenfy
Time: 9:30 am
day: Day Two
Details:
- Target engagement pattern is similar to Xanomeline, confirmed by qEEG
- Dual M1/M4 agonist
